$64.93
Price
$7.9B
Market Cap
—
P/E Ratio
-10.9
Forward P/E
$-6.30
EPS (TTM)
—
Dividend Yield
$963M
Cash
$789M
Total Debt
122M
Shares Out
$29.31
$70.98
52-Week Range
Institutional Ownership of CYTOKINETICS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for CYTOKINETICS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| No activity found for this stock. | |||||
Insider Trading for CYTOKINETICS INC
6 Months Insider Sentiment
Buy $0
Sell $8.8M
0
Buys
12
Sells
-8.8M
Net
5
Grants
Largest
$3.5M
Callos
$1.9M
MD
$1.3M
Wierenga
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 05, 2026 | Andrew Callos | EVP, Chief Commercial Officer | SELL | 15.0K | $60.28 | $904K |
| Jan 05, 2026 | Andrew Callos | EVP, Chief Commercial Officer | EXERCISE | 15.0K | $23.26 | $349K |
| Jan 02, 2026 | Andrew Callos | EVP, Chief Commercial Officer | SELL | 885 | $63.16 | $56K |
| Jan 02, 2026 | Andrew Callos | EVP, Chief Commercial Officer | EXERCISE | 885 | $37.63 | $33K |
| Jan 02, 2026 | Andrew Callos | EVP, Chief Commercial Officer | SELL | 913 | $62.09 | $57K |
| Dec 29, 2025 | Andrew Callos | EVP, Chief Commercial Officer | SELL | 1.8K | $62.44 | $113K |
| Dec 22, 2025 | Robert I Blum | President & CEO | GRANT | 5.8K | — | — |
| Dec 22, 2025 | Fady Ibraham Malik | EVP Research & Development | GRANT | 2.0K | — | — |
| Dec 22, 2025 | Robert I Blum | President & CEO | EXERCISE | 16.5K | $6.67 | $110K |
| Dec 22, 2025 | Andrew Callos | EVP, Chief Commercial Officer | GRANT | 1.6K | — | — |
| Dec 22, 2025 | Andrew Callos | EVP, Chief Commercial Officer | GRANT | 1.6K | — | — |
| Dec 22, 2025 | Wendell Wierenga | Director | SELL | 20.0K | $66.14 | $1.3M |
| Dec 22, 2025 | Wendell Wierenga | Director | EXERCISE | 20.0K | $7.61 | $152K |
| Dec 22, 2025 | Sung Lee | EVP, Chief Financial Officer | GRANT | 2.2K | — | — |
| Dec 22, 2025 | Robert I Blum | President & CEO | EXERCISE | 54.7K | $6.67 | $365K |
| Dec 16, 2025 | Fady Ibraham Malik | EVP Research & Development | SELL | 2.2K | $61.24 | $135K |
| Dec 16, 2025 | Fady Ibraham Malik | EVP Research & Development | EXERCISE | 2.2K | $10.60 | $23K |
| Dec 08, 2025 | Andrew Callos | EVP, Chief Commercial Officer | SELL | 1.0K | $65.96 | $69K |
| Dec 08, 2025 | Andrew Callos | EVP, Chief Commercial Officer | EXERCISE | 1.0K | $39.13 | $41K |
| Dec 05, 2025 | Andrew Callos | EVP, Chief Commercial Officer | EXERCISE | 10.6K | $37.63 | $400K |
| Dec 05, 2025 | Andrew Callos | EVP, Chief Commercial Officer | EXERCISE | 11.0K | $39.13 | $430K |
| Dec 05, 2025 | Andrew Callos | EVP, Chief Commercial Officer | EXERCISE | 15.0K | $23.26 | $349K |
| Dec 05, 2025 | Andrew Callos | EVP, Chief Commercial Officer | EXERCISE | 15.9K | $37.63 | $597K |
| Dec 05, 2025 | Andrew Callos | EVP, Chief Commercial Officer | SELL | 52.5K | $65.95 | $3.5M |
| Dec 02, 2025 | John T Henderson | Director | SELL | 8.8K | $63.90 | $559K |
| Dec 02, 2025 | John T Henderson | Director | EXERCISE | 8.8K | $10.00 | $88K |
| Dec 02, 2025 | Fady Ibraham Malik | EVP Research & Development | SELL | 2.2K | $63.89 | $141K |
| Dec 02, 2025 | Fady Ibraham Malik | EVP Research & Development | EXERCISE | 2.2K | $10.60 | $23K |
| Dec 01, 2025 | Edward M. Kaye MD | Director | EXERCISE | 8.1K | $12.40 | $100K |
| Dec 01, 2025 | Robert Arthur Harrington | Director | SELL | 2.1K | $66.80 | $144K |
| Dec 01, 2025 | Edward M. Kaye MD | Director | SELL | 28.1K | $66.72 | $1.9M |
| Dec 01, 2025 | Edward M. Kaye MD | Director | EXERCISE | 20.0K | $14.25 | $285K |